EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy

Paolo Sportoletti iD, Felice Bombaci, Chiara Cernetti, Alessandra Di Costanzo iD, Francesca Fiorentino, Sara Manurita, Andrea Marcellusi, Riccardo Mercati iD, Massimo Riccaboni iD, Chiara Vassallo iD, Antonio Cuneo iD

Hematological Oncology · 2026-11 · 44 (6)

DOI: 10.1002/hon.70274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 05.11.2026. Verfasst von Paolo Sportoletti und 10 weiteren Autor:innen. Beteiligte Einrichtung: Dipartmento di Medicina e Chirugia, Centro di Ricerca Emato-Oncologica (CREO), Universitá di Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Decision Support Techniques, Decision Making. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BeOne Medicines Ltd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in Western countries. The introduction of targeted therapies has expanded first‐line treatment options, which differ across multiple relevant dimensions, making therapeutic decisions increasingly challenging. A multi‐criteria decision analysis (MCDA) was conducted to identify and quantify the importance of key treatment selection criteria and to evaluate available first‐line alternatives for patients with mutated and unmutated immunoglobulin heavy‐chain variable region (IGHV mut /IGHV unmut ) gene status, from the perspective of clinicians, patients, payers, and methodologists. The analysis focused on targeted therapies recommended by European Society for Medical Oncology (ESMO) guidelines and reimbursed in Italy, including ibrutinib, acalabrutinib, zanubrutinib, venetoclax + ibrutinib, and venetoclax+obinutuzumab. The MCDA was developed in accordance with International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Good Practice recommendations, using the MACBETH (Measuring Attractiveness by a Categorical‐Based Evaluation Technique) method to elicit stakeholder preferences. Decision criteria were selected based on literature review, stakeholder input, and data availability. Preferences were collected from 20 stakeholders (nine clinicians, five patients, six payers/methodologists) via structured questionnaires. Six criteria were selected: efficacy, safety, quality of life (QoL), drug cost, convenience of administration, and treatment duration. Efficacy and safety emerged among the most important criteria across all groups, with efficacy particularly prioritized in the IGHV unmut population. Among the other criteria, notable differences emerged between stakeholder groups: clinicians assigned relatively greater importance to treatment duration, especially in the IGHV mut population; patients prioritized QoL more than other groups; payers and methodologists gave more weight to drug cost than clinicians and patients. In the IGHV mut population, venetoclax + ibrutinib, and zanubrutinib were the most valued options. In the IGHV unmut population, second‐generation Bruton tyrosine kinase inhibitors (zanubrutinib and acalabrutinib) ranked highest. Sensitivity analyses confirmed the robustness of these findings. This is the first MCDA study applied to CLL treatment in Italy. It highlights the value of structured, stakeholder‐informed approaches in supporting value‐based treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellDecision Support TechniquesDecision MakingHumansItaly

Stichwörter der Autor:innen

B‐cell lymphoma 2 inhibitorsItalychronic lymphocytic leukemiafirst‐line therapymulti‐criteria decision analysissurveys and questionnairestyrosine kinase inhibitors

Autor:innen und Institutionen

  • Dipartmento di Medicina e Chirugia, Centro di Ricerca Emato-Oncologica (CREO), Universitá di Perugia, Perugia, Italy.
  • AIL Patient Groups, Torino, Italy.
  • BeOne Medicines Italy Srl, Milan, Italy.
  • IQVIA Solutions Italy Srl, Real World Solutions, Milan, Italy.
  • Department of Pharmaceutical Science, University of Milan, Milan, Italy.
  • AxES, IMT School for Advanced Studies, Lucca, Italy.

ORCID-Profile: Paolo Sportoletti, Alessandra Di Costanzo, Riccardo Mercati, Massimo Riccaboni, Chiara Vassallo, Antonio Cuneo

Förderung

  • BeOne Medicines Ltd

Zitieren

APA

Sportoletti, P., Bombaci, F., Cernetti, C., Di Costanzo, A., Fiorentino, F., Manurita, S., Marcellusi, A., Mercati, R., Riccaboni, M., Vassallo, C., & Cuneo, A. (2026). Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy. Hematological Oncology, 44(6). https://doi.org/10.1002/hon.70274

Vancouver

Sportoletti P, Bombaci F, Cernetti C, Di Costanzo A, Fiorentino F, Manurita S, et al. Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy. Hematological Oncology. 2026;44(6). doi:10.1002/hon.70274

BibTeX
@article{Sportoletti2026,
  author = {Sportoletti, Paolo and Bombaci, Felice and Cernetti, Chiara and Di Costanzo, Alessandra and Fiorentino, Francesca and Manurita, Sara and Marcellusi, Andrea and Mercati, Riccardo and Riccaboni, Massimo and Vassallo, Chiara and Cuneo, Antonio},
  title = {Decision‐Making on First‐Line Treatment Alternatives in Chronic Lymphocytic Leukemia: A Multi‐Criteria Decision Analysis to Elicit Stakeholders' Preferences in Italy},
  journal = {Hematological Oncology},
  year = {2026},
  volume = {44},
  number = {6},
  doi = {10.1002/hon.70274}
}
Kostenlos starten →